Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Nov 23, 2022

Asaf Zviran is the CEO, CSO, and Co-Founder of C2i Genomics which is both a technology company and a diagnostic company. C2i is providing a decentralized, cloud-based platform that allows global genomic labs, health centers, and pharma companies to do whole-genome sequencing on cancer patient tissue or blood. This technology uses the genomic data to determine the best options for treatment and to monitor treatment response.

Asaf explains, "The way that we look at the cancer detection is in a holistic way. We're actually detecting huge amounts of features across the genome in a very, very sensitive and accurate manner. Many clinical trials have been showing that the C2i whole-genome approach is much more sensitive and accurate than any other technology that is currently in development."

"Whole-genome, I think is a new category in medical genomics in general. Whole-genome allows us to very comprehensively extract everything, all of the variants, all of the genomic changes, in the patient blood. And then the challenge again is how to use this very comprehensive information to create insight, to create applications. This is exactly what C2i is doing. Basically, we are building out clinically validated software applications that can take the whole-genome data, the whole data from the apps that are working with us, and allow very sophisticated AI signal processing to detect cancer, to monitor treatment response, to predict recurrence."

"And we are doing that on a global scale. I can tell you that besides our CLIA-equipped lab in the US, we are working in partnership to deliver these services to other health systems in the US. We are a clinical-approved product in Europe, and starting to do clinical testing and working extensively in Europe. We also have a very strong distribution in the Middle East and Asia. So Israel, Singapore, India, and now going into a new location in Asia."

#C2iGenomics #WholeGenome  #WholeGenomeSequencing #PrecisionMedicine #Cancer #Tumors #AI #MedicalGenomics

Listen to the podcast here

C2i Genomics